Clinical Trial Update: Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of co-administered lanreotide Autogel at 60/90/120 mg with lanreotide prolonged-release 40 mg in acromegaly; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• Lanreotide Autogel (lanreotide)
• Lanreotide Prolonged Release (PR) (lanreotide)

Snippet

Sponsor: Ipsen | Conditions: Acromegaly | Phase 3 | Status: COMPLETED | Results posted: 2018-12-14